The first Molecular Analysis for Personalised Therapy (MAP) meeting will be held in Paris, Ocotber 23-24.
A joint initiative of UNICANCER, ESMO and Cancer Research UK, this new conference will explore clinical interpretation of molecular tests for metastatic cancers.
The development of new biotechnologies has revolutionised the applications of personalised therapy in metastatic cancer. Multigene sequencing for cancer patients is now possible.
The MAP Conference will equip clinicians and researchers to interpret clearly the molecular analyses of their patients.
Scientific presentations by international leaders that will hightlight the latest advances in the field of personalised medicine for cancer patients.
Genomic clinical cases that will offer some real-life examples of clinical interpretation in the field of genetic science.
Roundtable discussions that will allow participants to exchange on ho to prioritise targets in cancer patients.
Jean-Charles Soria, Gustave Roussy, Villejuif, France
Charles Swanton, London Research Institute, UK
Fabrice André, Gustave Roussy, Villejuif, France
Pascale Flamant, Déléguée générale, Fédération UNICANCER
Ian Walker, CEO, Cancer Research UK
Alessia Mora, Head of Congress Department, ESMO
Local host committee
Christophe Jamain, Direction scientifique R&D UNICANCER
Agathe Lasne, Chargée de communication, UNICANCER